Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma plus Gedatolisib in HER2+ Metastatic Breast Cancer
NCT03698383Phase 2Unknown
- Sponsor
- Korean Cancer Study Group
- Start
- Dec 2019
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gedatolisib in HER2-positive breast cancer and breast cancer, sponsored by Korean Cancer Study Group. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
gedatolisib
03
Conditions
HER2-positive breast cancerbreast cancer
Beyond the preview
Go deeper on NCT03698383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698383.